People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | — | Biotechnology | Series D+ | $314.5M | $420.8M | 2010 |
| Centrexion Therapeutics Corp | — | Biotechnology | Series C | $202.0M | $35.3M | 2017 |
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2014 |
| InspireMD, Inc. | — | Other Health Care | Series C | $117.2M | $248.3M | 2011 |
| Edge Therapeutics, Inc. | — | Pharmaceuticals | Series C | $72.1M | $2.0B | 2013 |
| Aevi Genomic Medicine, Inc. | — | Biotechnology | Series B | $45.4M | $1.1B | 2015 |
Sol J. Barer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sol J. Barer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 3 | 14 |
| Sol Barer | 3 | 6 |
| Isaac J. Blech | 2 | 3 |
| James J. Loughlin | 2 | 2 |
| Arnold Oronsky | 1 | 10 |
| P. Sherrill Neff | 1 | 8 |
| David Clark | 1 | 8 |
| Michael Berman | 1 | 7 |
| EUGENE A. BAUER | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Arnold L. Oronsky | 1 | 6 |
| Ted W. Love | 1 | 5 |
| MICHAEL J. WARD | 1 | 5 |
| Donald J. Hayden, Jr. | 1 | 5 |
| Bradley Campbell | 1 | 5 |
| James N. Topper | 1 | 5 |
| James Barry | 1 | 5 |
| Asher Holzer | 1 | 4 |
| Phil Gutry | 1 | 4 |
| ULI HACKSELL | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.